Disease landscape

Chronic Lymphocytic Leukemia (CLL) clinical trials

Get alerts when Chronic Lymphocytic Leukemia (CLL) trials change

362 active trials 180 recruiting 42 Phase 3 169 sponsors 65 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 42 of 65 changes on 20 trials

2026-08-20
Primary completion pushed: 2029-05 → 2030-12
Enrollment reduced: 110 → 66 participants
Enrollment closed, study ongoing
Completion pushed: 2029-05 → 2030-12
NCT02966756 A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic… · AbbVie · Phase 2
2026-07-30
Primary completion pushed: 2026-05 → 2029-08
Completion pushed: 2026-06 → 2029-08
NCT05645107 A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT)… · Grifols Therapeutics LLC · Phase 3
2026-08-06
Primary completion pushed: 2026-07-31 → 2028-12-31
Completion pushed: 2026-10-31 → 2029-12-31
NCT06506643 Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms · Vector Vitale LLC · Phase 1/2
2026-08-28
Primary completion pushed: 2026-07 → 2027-07
Completion pushed: 2026-07 → 2027-07
NCT04464200 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · Memorial Sloan Kettering Cancer Center · Phase 1
2026-08-01
Primary completion pushed: 2026-03 → 2028-01
Primary endpoint(s) modified
Enrollment increased: 66 → 84 participants
Completion pushed: 2028-04 → 2028-07
Trial arms changed: 8 → 12
NCT06708897 A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies · Lomond Therapeutics Holdings, Inc. · Phase 1
2026-08-18
Primary completion pushed: 2026-02-01 → 2026-12-24
Completion pushed: 2026-06-30 → 2026-12-30
NCT06001385 HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced… · Center for International Blood and Marrow Transplant Research · Phase 2
2026-08-05
Primary completion pushed: 2026-12-31 → 2029-03-31
Primary endpoint(s) modified
Completion pushed: 2026-12-31 → 2029-03-31
Trial arms changed: 0 → 2
NCT05999877 PICAROS - Acalabrutinib RWE on 1L CLL in Spain · AstraZeneca
2026-07-30
Primary completion pushed: 2027-01-01 → 2027-07-01
NCT07459608 Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell… · Henan Cancer Hospital · Phase 2
2026-08-21
Primary completion pushed: 2026-08-01 → 2027-08-01
Completion pushed: 2027-08-01 → 2028-08-01
NCT04007029 Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or… · Jonsson Comprehensive Cancer Center · Phase 1
2026-08-11
Primary completion pushed: 2026-03-09 → 2026-08-09
Primary endpoint(s) modified
Enrollment reduced: 60 → 24 participants
Trial status changed: Enrolling by Invitation → Recruiting
Trial arms changed: 4 → 3
NCT06762431 Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant… · Vitebsk Regional Clinical Cancer Centre · Phase 1/2
2026-08-22
Primary endpoint(s) modified
NCT05006716 A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With… · BeOne Medicines · Phase 1/2
2026-08-11
Enrollment reduced: 90 → 59 participants
Enrollment closed, study ongoing
NCT03128879 Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL · M.D. Anderson Cancer Center · Phase 2
2026-07-31
Recruitment opened
NCT07609823 A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL · Guangzhou Lupeng Pharmaceutical Company LTD. · Phase 2
2026-07-31
Recruitment opened
NCT07609862 A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies · Guangzhou Lupeng Pharmaceutical Company LTD. · Phase 1/2
2026-08-27
Trial status changed: Suspended → Active, Not Recruiting
NCT07166419 Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the… · Ohio State University Comprehensive Cancer Center · Phase 1
2026-07-31
Recruitment opened
Trial sites expanded: 2 → 6 locations
NCT07424833 A Study of APG-3288 in Relapsed/Refractory Blood Cancers · Ascentage Pharma Group Inc. · Phase 1
2026-08-21
Trial completed
Completion moved earlier: 2026-07-22 → 2025-07-31
NCT04981912 Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL… · University of California, San Diego · Phase 1
2026-08-27
Trial sites expanded: 204 → 209 locations
NCT06973187 A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to… · BeOne Medicines · Phase 3
2026-08-28
Trial sites expanded: 0 → 3 locations
NCT07709000 A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) · Merck Sharp & Dohme LLC · Phase 2
2026-08-25
Trial sites expanded: 127 → 130 locations
NCT06846671 A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants… · BeOne Medicines · Phase 3

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-19 NCT07774390 Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL European Research Initiative on CLL new
2026-08-13 NCT07763054 Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia… Haikou Affiliated Hospital of Central South University Xiangya School of Medicine new
2026-08-07 NCT07753369 A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus… Chia Tai Tianqing Pharmaceutical Group Co., Ltd. new Phase 3
2026-08-04 NCT07744750 Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma Changzhou No.2 People's Hospital new Phase 2
2026-08-03 NCT07741695 Targeting IRAK4 in Chronic Lymphocytic Leukemia IRCCS San Raffaele new
2026-07-17 NCT07711327 Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase… Tina Baykaner new
2026-07-08 NCT07691047 Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic… Private Hospital of Confluent, France new
2026-07-02 NCT07682415 Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax… Yi Shuhua new Phase 2
2026-07-01 NCT07679919 BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies Luminary Therapeutics new Phase 1
2026-06-26 NCT07671378 A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL… The First Affiliated Hospital with Nanjing Medical University new Phase 2

Active trials by phase

Early Phase 1
4
Phase 1
66
Phase 1/2
39
Phase 2
121
Phase 2/3
1
Phase 3
41
Phase 4
5
Not charted: 85 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 362

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT07218341 A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic… Eli Lilly and Company Recruiting 2026-08-21
NCT06651970 Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL… AstraZeneca Recruiting 2026-08-14
NCT06876649 A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib Eli Lilly and Company Recruiting 2026-03-02
NCT06876662 A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic… Eli Lilly and Company Recruiting 2026-03-02
NCT04790045 Lymph Node Microenvironment Modifications in Patients With CLL Treated With… Paolo Ghia Not Yet Recruiting 2023-10-03
Phase 3
NCT04269902 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or… National Cancer Institute (NCI) Recruiting 2026-08-27
NCT05947851 A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line… Merck Sharp & Dohme LLC Recruiting 2026-08-27
NCT06136559 A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib… Merck Sharp & Dohme LLC Recruiting 2026-08-27
NCT06973187 A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to… BeOne Medicines Recruiting 2026-08-26
NCT06846671 A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants… BeOne Medicines Recruiting 2026-08-24
NCT06943872 A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or… BeOne Medicines Recruiting 2026-08-24
NCT05197192 A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and… German CLL Study Group Recruiting 2026-08-20
NCT07277231 A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With… BeOne Medicines Recruiting 2026-08-19
NCT05254743 A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic… Loxo Oncology, Inc. Recruiting 2026-08-17
NCT07342478 ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R… Newave Pharmaceutical Inc Recruiting 2026-08-11
NCT07509151 Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia… AstraZeneca Recruiting 2026-08-10
NCT07321652 Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment… Alliance for Clinical Trials in Oncology Recruiting 2026-08-05
NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) Janssen Research & Development, LLC Recruiting 2026-07-31
NCT05645107 A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT)… Grifols Therapeutics LLC Recruiting 2026-07-29
NCT06319456 A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy… Ascentage Pharma Group Inc. Recruiting 2026-07-28
NCT06104566 Global Trial in APG2575 for Patients With CLL/SLL Ascentage Pharma Group Inc. Recruiting 2026-06-18
NCT07139873 A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) Dizal Pharmaceuticals Recruiting 2026-06-03
NCT07582432 A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in… Grifols Biologicals, LLC Recruiting 2026-05-12
NCT06428019 A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants… AbbVie Recruiting 2026-04-09
NCT02477696 Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With… Acerta Pharma BV Active, Not Recruiting 2026-08-26
See all 362 active Chronic Lymphocytic Leukemia (CLL) trials with filters →

Top sponsors by active trials in this area

City of Hope Medical Center (18) · AstraZeneca (16) · M.D. Anderson Cancer Center (15) · National Cancer Institute (NCI) (12) · AbbVie (10) · Mayo Clinic (10) · BeOne Medicines (9) · Acerta Pharma BV (8) · Dana-Farber Cancer Institute (8) · Ascentage Pharma Group Inc. (7)

Get alerts when Chronic Lymphocytic Leukemia (CLL) trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free